Real-world data (RWD) has evolved from a supplementary asset to a critical driver of modern biopharma strategy. In this interview, Dan Jacob, Vice President and General Manager of Real World Data Solutions at Labcorp, defines RWD as the digital breadcrumbs generated throughout patient care, from electronic health records and claims to lab tests and wearable data. When combined and analyzed, these data become real-world evidence (RWE), enabling deeper insights into patient journeys and outcomes beyond traditional clinical trials.
The growing availability of digitized healthcare data has accelerated this shift, allowing researchers to uncover real-time signals and generate meaningful insights faster than ever before. According to Dan, this evolution has helped biopharma identify new treatment opportunities, improve patient outcomes, and engage regulators with stronger evidence. At the same time, the industry faces persistent data challenges, including latency, lack of transparency, and gaps in diagnostic and genetic data, representing areas where high-quality, source-verified data is increasingly vital.
Looking ahead, the integration of biomarker and genetic data is enabling more precise, personalized medicine and targeted clinical trials. As AI and advanced analytics continue to expand, the importance of high-fidelity, well-curated data becomes even more critical. Dan emphasizes that the future of innovation in healthcare will depend on trusted and interoperable data sources as well as systems, and strategic partnerships that can unlock deeper, more actionable insights across the patient journey.
The editorial staff had no role in this post's creation.